Introduction {#s0005}
============

Cancer is among the leading causes of mortality worldwide [@bb0005]. The greatest therapeutic challenge it poses is its cellular heterogeneity, probably the product of clonal evolution [@bb0010] and/or cancer stem cells (CSC) [@bb0015]. CSCs are more resistant to conventional cancer therapies than non-CSC populations [@bb0020], [@bb0025], [@bb0030] and more likely to cause cancer recurrences [@bb0035]. Current cancer treatments including chemotherapy, γ-irradiation and immunotherapy eliminate cancer cells mostly through activating apoptosis pathways [@bb0040], [@bb0045], [@bb0050]. However, recent studies demonstrated that cancer cell lines could survive apoptosis induction and the reversed cancer cells possessed some features of CSCs and became more aggressive [@bb0055], [@bb0060], [@bb0065].

Here, we showed that breast cancer cells undergoing reversal of apoptosis acquired increased tumorigenicity both *in vitro* and *in vivo* and there was a correlated elevation of the percentage of cells with CSC markers in the reversed cells comparing with the untreated ones. Importantly, this reversal process triggered a transition from non-stem cancer cells (NSCCs) to CSCs, which could be suppressed by pre-treatment with epigenetic modulators. These results suggest that targeting the epigenetic regulation could be a promising strategy for decreasing CSCs and hence tumorigenicity and/or metastasis.

Materials and Methods {#s0010}
=====================

Cell Culture and Apoptosis Induction {#s0015}
------------------------------------

The culture of MCF-7, T47D and MDA-MB-231 (American Type Culture Collection, Manassas, VA, USA) were done as described in the Supplementary data. 2.5 μM staurosporine (STS) (Sigma-Aldrich, St. Louis, MO, USA) and 5 μM paclitaxel (Sigma-Aldrich) were applied to MCF-7 cells for 6 hours and to T47D cells for 10 hours, respectively, to induce apoptosis when cell density reached 70% confluency. Solvent controls of STS and paclitaxel were 0.25% v/v and 0.05% v/v dimethyl sulfoxide (DMSO) (Sigma-Aldrich) respectively.

CellEvent™ Staining and Fluorescence-Activated Cell Sorting (FACS) {#s0020}
------------------------------------------------------------------

Apoptotic MCF-7 and T47D cells were stained with 3 μM CellEvent™ (Invitrogen, Carlsbad, CA, USA) at a cell concentration of 10^6^ cells/mL in the dark for 30 minutes at 37°C. Cells were then filtered through a 40-μm nylon mesh (BD Biosciences, Bedford, MA, USA) before running on the Bio-Rad S3 sorter (Bio-Rad, Hercules, CA, USA) (refer to Supplementary data for details on cell sorting and the subsequent procedure for culturing of cells undergoing apoptosis reversal).

Propidium Iodide (PI) Staining for Live/Dead Cell Detection {#s0025}
-----------------------------------------------------------

Cells were collected, washed twice with phosphate buffered saline (PBS) and stained with 2 μg/mL PI (Thermo Fisher Scientific, Waltham, MA, USA) just before running on the BD FACSVerse flow cytometer (BD Biosciences).

In Vivo Tumorigenicity Assay {#s0030}
----------------------------

The following experimental procedures were approved by the Animal Ethics Committee, the Chinese University of Hong Kong and conformed to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (NIH Publication, 8th Edition, 2011). Single MCF-7 cells were resuspended in 50 μL serum-free RPMI 1640 and mixed with Growth Factor Reduced Matrigel Matrix (BD Biosciences) at 1:1 ratio (v:v) and injected subcutaneously into the mammary fat pad of anesthetized 6-week old female nude mice (refer to Supplementary data for details on animal surgery). The control group received only serum-free RPMI 1640 medium and Matrigel mixture (1:1). Tumor volumes were determined every 3 days. Tumor volume (mm^3^) = 0.52 × width (mm)^2^ × length (mm).

Mammosphere Culture {#s0035}
-------------------

Single cell suspension was plated in an ultra-low attachment 6-well plate (Corning, NY, USA) at a density of 4 × 10^4^ cells/mL in the primary or 10^4^ cells/mL in the secondary and tertiary mammosphere formation experiments. The culture condition for mammosphere formation was described in the Supplementary data. Mammosphere formation efficiency (MFE) (%) = (number of mammospheres per well / number of cells seeded per well) × 100. Only mammospheres with a diameter of ≥60 μm were counted at the end of each passage (day 7).

Immunohistochemical Analysis {#s0040}
----------------------------

Tissues and xenograft tumors were fixed and sectioned for analysis (refer to Supplementary data for details on slice preparation). For detection of CSC markers, fluorochrome-conjugated antibodies against human CD44 (PERCP-CY5.5, BD Biosciences) and CD24 (PE, BD Biosciences) were added at 1:40 and 1:10 dilution, respectively. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) at 1:5000 dilution. For EMT markers, sections were incubated with mouse anti-E-Cadherin (BD Biosciences) and rabbit anti-N-Cadherin antibodies (Abcam, Cambridge, UK) at 4°C overnight, followed by goat anti-mouse Alexa Fluor® 488- and goat anti-rabbit Alexa Fluor® 594-labeled secondary antibodies (Thermo Fisher Scientific).

Immunostaining Followed by Flow Cytometric and Confocal Analysis {#s0045}
----------------------------------------------------------------

For preparing cells for flow cytometry, cells were blocked with 1:50 diluted Fc block (Miltenyi Biotec, Auburn, CA, USA) for 20 minutes. For preparing cells for confocal microscopy, cells were fixed, permeabilized and blocked with 1% BSA and 5% normal goat serum (Invitrogen) for 1 hour. In both cases, antibodies against human CD44 (PERCP-CY5.5, BD Biosciences) and CD24 (PE, BD Biosciences) were added at 1:40 and 1:10 dilution, respectively, and incubated at 4°C in dark. For flow cytometry, cells were analyzed on FACSVerse equipped with FACSuite software (BD Biosciences). For confocal analysis, images were acquired using the Olympus FluoView FV1000 confocal laser scanning microscope with a 60X objective and analyzed using the FV1000 software (Olympus, Tokyo, Japan) (refer to Supplementary data for details).

FACS of NSCCs {#s0050}
-------------

CSCs in breast cancer were defined as CD44^+^/CD24^-^ cells, and NSCCs were defined as CD44^-^/CD24^+^ cells. Cells were immunostained under identical conditions as described above and CSCs and NSCCs were collected using Bio-Rad S3 sorter. Sorted NSCCs were cultured in the collection medium for 7 days before STS (or solvent control) treatment as described in the \'basic procedure for apoptosis induction and reversal of apoptosis\' in Supplementary data.

Isolation of Limited Numbers of CSCs by Magnetic-Activated Cell Sorting (MACS) Using Dynabeads® {#s0055}
-----------------------------------------------------------------------------------------------

NSCCs in MCF-7 were obtained through FACS and reversal of apoptosis was done as described above. Reversed NSCC (NSR) cells were harvested at day 7. Then, MACS using Dynabeads® (Invitrogen) was first applied for CD24 negative selection to collect CD24^-^ cells, followed by a CD44 positive selection to eventually obtain the CD44^+^/CD24^-^ (CSC) population. Cells remaining after this sorting procedure were named NCSCs.

Reverse Transcription Followed by Real-time PCR (RT-qPCR) {#s0060}
---------------------------------------------------------

mRNA was extracted and reverse-transcribed to cDNA using SuperScript® III 1^st^ Strand Synthesis System (Invitrogen). Real-time PCR was performed as described in the Supplementary data.

Bisulfite Conversion and Methylation-Specific PCR (MSP) {#s0065}
-------------------------------------------------------

Genomic DNA was extracted and bisulfite conversion of DNA was performed using the EpiTect Bisulfite Kit (Qiagen, Duesseldorf, Germany). For methylation analyses of the promoter regions of CD44 and CD24, two rounds of end-point PCR were performed (refer to Supplementary data for details).

Epigenetic Modulator Experiments {#s0070}
--------------------------------

FACS-sorted NSCCs were treated with 5 μM 5-Azacytidine (5-Aza) (Sigma-Aldrich) or 0.5 mM S-(5′-Adenosyl)-L-methionine chloride dihydrochloride (SAM) (Sigma-Aldrich). Solvent was used as control. The media containing the drugs were replaced every 24 hours and the cells were treated for a total of 72 hours before procedure for apoptosis reversal (refer to Supplementary data for details).

Live Cell Imaging {#s0075}
-----------------

Cells were stained sequentially with CellEvent™, Mitotracker Red CMXRos (Invitrogen) and Hoechst 33342 (Invitrogen) (refer to Supplementary data for details). Cell morphology was observed using the Olympus FluoView FV1000 confocal laser scanning microscope with a 60X objective and further analyzed using the FV1000 software.

Western Blotting {#s0080}
----------------

Total proteins were extracted from cells and analyzed by Western blotting. Immunodetection were performed using anti-PARP at 1:1000 dilution(Cell Signaling, Danvers, MA, USA) and anti-β-tubulin (1:1000 dilution) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) (refer to Supplementary data for details).

Results {#s0085}
=======

Apoptosis Reversal Increased Tumorigenicity of Breast Cancer Cells In Vitro and In Vivo {#s0090}
---------------------------------------------------------------------------------------

First, to show how apoptosis reversal affects tumorigenesis, we used the MCF-7 cell line and apoptotic inducer, STS [@bb0070], to build an apoptosis reversal model ([Supplementary Figure 1](#f0025){ref-type="graphic"}*A*). Typical apoptotic morphological changes, including cell shrinkage, membrane blebbing, mitochondrial fragmentation and nuclear condensation, were observed 6 hours after STS treatment. Twenty-four hours after replacing STS with fresh medium, cells appeared to recover ([Supplementary Figure 1](#f0025){ref-type="graphic"}*B*). Western blotting revealed that poly (ADP-ribose) polymerase (PARP) was cleaved after STS treatment, confirming the activation of caspase, a biochemical marker of apoptosis ([Supplementary Figure 1](#f0025){ref-type="graphic"}*C*). To show that apoptosis reversal induced transformation of NSCCs to CSCs is not restricted to a particular cell line, another breast cancer cell line T47D was treated with the chemotherapy drug paclitaxel. Chemotherapy so far has been the mainstay in breast cancer treatment and paclitaxel is one of the clinically used drug for breast cancer [@bb0075], [@bb0080]. The mechanism of action of paclitaxel involves its interference with microtubule assembly during mitosis [@bb0085], [@bb0090] and its inhibition on the anti-apoptosis protein Bcl-2 to induce apoptosis in cancer cells [@bb0095]. Similar to the treatment of MCF-7 with STS, after 10 hours of paclitaxel induction, characteristic changes in cell morphology were also observed in T47D and cells regained their normal morphology after drug removal and medium replenishment for 24 hours ([Supplementary Figure 1](#f0025){ref-type="graphic"}*D*). We then labeled caspase-activated cells using CellEvent™ and isolated them through fluorescence-activated cell sorting (FACS) ([Supplementary Figure 1](#f0025){ref-type="graphic"}*E*). In parallel, DMSO-treated cells were also stained with CellEvent™, and CellEvent™-negative cells were collected as solvent control ([Supplementary Figure 1](#f0025){ref-type="graphic"}*E*). Both MCF-7 and T47D cells that recovered from apoptosis were viable, able to proliferate and had morphology similar to untreated and solvent-treated cells ([Supplementary Figure 1](#f0025){ref-type="graphic"}*F*).

In order to demonstrate that reversal of apoptosis was not a process to select drug-resistant cells, we prolonged the induction of apoptosis to reveal the fate of both CellEvent™-positive and CellEvent™-negative cells. Cells after STS or paclitaxel treatment were stained with CellEvent™ and FACS-sorted. Unlike the reversal steps, the sorted cells were cultured back in the medium with previous inducers for another 24 hours before PI staining and microscopy detection. In parallel, some sorted cells were put into fresh medium without drug ([Supplementary Figure 2](#f0030){ref-type="graphic"}*A*). Without the reversal steps, both CellEvent™-positive and CellEvent™-negative cells were kept dying in the continuous apoptotic induction ([Supplementary Figures 2](#f0030){ref-type="graphic"}*B*-*E* and [3](#f0035){ref-type="graphic"}*A* and *B*), which exclude the possibility that drug-resistant cells were preferably selected during apoptosis reversal. In contrast, under the reversal protocol, attached cells that were put back into fresh medium owned normal morphology with intact cell membrane function ([Supplementary Figures 2](#f0030){ref-type="graphic"}*B*-*E* and [3](#f0035){ref-type="graphic"}*A* and *B*).

FACS-sorted MCF-7 cells were then used for *in-vitro* and *in-vivo* tumorigenicity analyses ([Supplementary Figure 4](#f0040){ref-type="graphic"}). All sorted cells retained their tumorsphere-forming ability [@bb0100] ([Figure 1](#f0005){ref-type="fig"}*A*), which was significantly enhanced in the reversed cells after one week of culture compared to the solvent control or untreated cells. The ability to maintain mammospheres in serial suspension passage is related to the stem cells\' self-renewal ability [@bb0105], [@bb0110], thus, mammospheres were usually digested and passed for more passages [@bb0115], [@bb0120]. In our experiment, the ability of the reversed cells to form mammospheres was observed to persist through two subsequent serial passages ([Figure 1](#f0005){ref-type="fig"}*B*). On the other hand, it is now realized that tumor-initiating cells have plasticity and their "stemness" could be affected by extrinsic factors in the microenvironment [@bb0125], [@bb0130], which were not always supplemented in the *in vitro* culture condition. Thus, the tumor transplantation in immunodeficient mice is the current "gold standard" for identifying CSCs [@bb0090], [@bb0130]. Tumorigenicity of the reversed cells was assessed *in vivo* by injecting them into the mammary fat pads of 6-week-old female nude mice ([Supplementary Figure 4](#f0040){ref-type="graphic"}). Among the 50,000-injected-cell groups, transplanted reversed cells led to rapid tumor development, with visible tumors emerging at 2 weeks after injection while visible tumors did not appear until after 4 weeks for the solvent-control and untreated groups ([Figure 1](#f0005){ref-type="fig"}*C*). The mean final tumor size ([Figure 1](#f0005){ref-type="fig"}*C* and [Supplementary Figure 5](#f0045){ref-type="graphic"}) and mean final tumor weight ([Figure 1](#f0005){ref-type="fig"}*D*) was significantly greater in the reversed group than in the control groups. Among the 10,000-injected-cell groups, tumors were first detected at about 4 weeks after injection of the reversed cells while no tumor was found in the control groups throughout the experiment ([Figure 1](#f0005){ref-type="fig"}*C* and [Supplementary Figure 5](#f0045){ref-type="graphic"}). Tumors derived from all 3 cell types possessed similar morphologies ([Figure 1](#f0005){ref-type="fig"}*E*).

Autopsy revealed that in the 50,000 reversed-cell group, lymph node metastasis was detected in 4 out of 8 mice ([Figure 2](#f0010){ref-type="fig"}*A*). Immunostaining of epithelial-mesenchymal transition (EMT) markers revealed that primary tumors formed from both solvent control and untreated cells expressed the epithelial marker E-cadherin [@bb0135] while those from reversed cells expressed the mesenchymal marker N-cadherin ([Figure 2](#f0010){ref-type="fig"}*B*). Interestingly, the metastasis detected in the lymph node re-expressed E-cadherin ([Figure 2](#f0010){ref-type="fig"}*C*). The same epithelial/mesenchymal expression patterns were also found in cells undergoing apoptosis reversal *in vitro* ([Figure 2](#f0010){ref-type="fig"}*D*). Transcript levels of N-cadherin and other mesenchymal markers including fibronectin and vimentin [@bb0140] in cultured reversed cells were all elevated when compared to those in solvent control cells ([Figure 2](#f0010){ref-type="fig"}*E*).Figure 1Reversed MCF-7 cells showed increased tumorigenicity *in vitro* and *in vivo*.(A) Mammospheres formed by reversed, solvent control and untreated cells. Scale bar: 500 μm. (B) Mammosphere formation efficiency of the three passages of reversed, solvent control and untreated cells. Data represent mean±SEM. (*n* = 3). \*\*\**P* \< .001. (C) Kinetics of the *in-vivo* xenograft assay. Data represent mean±SEM. (*n* = 8). (D) Final tumor weight of xenografts. R: reversed cells; SC: solvent control; UT: untreated. Horizontal bar in the middle of each data cluster represents mean±SEM. \*\*\*/\#\#\#*P* \< .001; \*\**P* \< .01. (E) H&E-stained xenografts from the initial injection of 50,000 cells in reversed, solvent control and untreated groups. Scale bar: 200 μm.Figure 1Figure 2EMT occurred during apoptosis reversal both *in vitro* and *in vivo.*(A) H&E-stained sectioned organs from tumor-bearing mice in the 50,000-injected-cell groups versus normal mice. Scale bar: 100 μm. (B) Immunofluorescence images of E-cadherin (green) and N-cadherin (red) in reversed (top), solvent control (middle) and untreated (bottom) MCF-7 xenografts. Scale bar: 25 μm. (C) H&E-stained and immunofluorescence images showing a tumor (T) in the lymph node (LN) from the reversed MCF-7 group (top) and a normal lymph node (bottom). Dash line indicates the LN-T boundary. Scale bar: 50 μm (H&E); 25 μm (confocal). (D) Immunofluorescence images showing the switch from epithelial (E-cadherin, green) to mesenchymal marker (N-cadherin, magenta) in reversed cells. Scale bar: 25 μm. (B-D) Nuclei were stained with DAPI. (E) Relative expressions of mesenchymal markers in the reversed and solvent control cells. Data represent mean±SEM (*n* = 3). \*\**P* \< .01; \*\*\**P* \< .001.Figure 2

CD44^+^/CD24^-^ CSC-Like Cells Were Transited from NSCCs During Apoptosis Reversal {#s0095}
----------------------------------------------------------------------------------

Next, we used flow cytometry to evaluate the percentage of tumor-initiating or CSC-like cells before and after apoptosis reversal, based on the expression of two cell-surface markers, CD44 and CD24 [@bb0040]. Cells with the CD44^-^/CD24^+^ configuration were designated as NSCCs, while those with CD44^+^/CD24^-^ were designated as CSC-like cells [@bb0145]. We found that, as in previous studies [@bb0150], \<2% (\~0.1% in our case) of untreated MCF-7 cells were CD44^+^/CD24^-^ ([Figure 3](#f0015){ref-type="fig"}*A*), whereas the percentage of reversed cells that were CD44^+^/CD24^-^ was significantly elevated ([Figure 3](#f0015){ref-type="fig"}*A* and *B*). Higher CD44 and lower CD24 expressions were separately observed in the reversed MCF-7 population than in the control groups ([Figure 3](#f0015){ref-type="fig"}*C* and *D*). Further confirmation was provided by immunostaining of these two markers in cultured MCF-7 cells ([Supplementary Figure 6](#f0050){ref-type="graphic"}*A*), and in the corresponding tumor sections ([Supplementary Figure 6](#f0050){ref-type="graphic"}*B*). Although the increased percentage of CSC-like cells in the reversed population could be attributed to the enrichment of pre-existing CSCs present in the cell population before treatment [@bb0155], an alternative explanation could be that some of the original NSCCs were transformed into new CSCs by apoptosis reversal. To test the latter hypothesis, we induced apoptosis in NSCCs from untreated cells. CellEvent™ staining and FACS were used to isolate caspase-activated cells. Solvent-treated NSCC controls were sorted in parallel ([Supplementary Figure 7](#f0055){ref-type="graphic"}). We were able to show that new CSCs could originate from NSCCs after apoptosis reversal (NSR) since no CSC was observed among NSCCs treated with solvent only (NSSC) or untreated NSCCs (NSUT) ([Figure 3](#f0015){ref-type="fig"}*E* and *F*). Moreover, these NSRs formed stable spheroids in the *in-vitro* mammosphere assay while NSSCs and NSUTs failed to yield any mammosphere ([Figure 3](#f0015){ref-type="fig"}*G* and *H*).

The discovery on NSCC to CSC transition during apoptosis reversal prompted us to investigate whether this phenomenon was repeatable in different apoptotic induction condition and in other cancer cell line. Unlike MCF-7 cells, there was no CSCs detectable in untreated T47D population ([Figure 3](#f0015){ref-type="fig"}*I*). Results from T47D-paclitaxel model showed that after reversal of apoptosis, CD44^+^/CD24^-^ cells appeared in the population, which could not be detected in the solvent control group ([Figure 3](#f0015){ref-type="fig"}*I* and *J*). Consistently, the increase of CD44 and decrease of CD24 expressions were significant in the reversed T47D cells when compared to untreated and solvent control groups ([Figure 3](#f0015){ref-type="fig"}*K* and *L*). These results suggested that reversal of apoptosis assists the transformation of NSCCs to CSCs and this is a general phenomenon in breast cancer cells.Figure 3Reversed breast cancer cells have higher percentage of cells with CSC markers (CD44^+^/CD24^-^).(A) Distributions of MCF-7 cells expressing CD44 and CD24 in reversed, solvent control or untreated group. More cells had CSC markers (CD44^+^/CD24^-^) (Q3) after apoptosis reversal. (B-D) Percentage of MCF-7 cells expressing CD44^+^/CD24^-^ (B), CD44^+^ (C) and CD24^+^ (D). Data represent mean±SEM. (*n* = 6). \*\**P* \< .01; \*\*\**P* \< .001. (E) Expressions of CD44 and CD24 in reversed NSCC (NSR), solvent control NSCC (NSSC) and untreated NSCC (NSUT) cells by FACS analyses. (F) Percentages of CD44^+^/CD24^-^ cells in all three groups. Data represent mean±SEM (*n* = 3). \*\*\**P* \< .001. n.d.: not detected. (G) Inverted microscopic images of mammospheres formed by NSRs, NSSCs and NSUTs. Scale bar: 500 μm. (H) Mammosphere formation efficiencies of the three passages of NSRs, NSSCs and NSUTs. Data represent mean±SEM (*n* = 3). \*\*\**P* \< .001. n.d.: not detected. (I) Distributions of T47D cells expressing CD44 and CD24 in reversed, solvent control or untreated group. Some cells possessed CSC markers (CD44^+^/CD24^-^) (Q3) after apoptosis reversal. (J-L) Percentage of T47D cells expressing CD44^+^/CD24^-^ (J), CD44^+^ (K) and CD24^+^ (L). Data represent mean±SEM. (*n* = 3). \**P* \< .05; \*\**P* \< .01.Figure 3Figure 4Dynamic regulation of *CD44* and *CD24* methylation statuses during apoptosis reversal.(A and B) Relative expressions (A) and methylation statuses by methylation-specific PCR (B) of *CD44* and *CD24* in reversed versus solvent control cells. (C and D) Relative expressions (C) and methylation statuses (D) of *CD44* and *CD24* in CSCs and NCSCs sorted from NSRs. (B and D) MCtrl and UCtrl: methylated and unmethylated bisulfite-converted control human DNA; CD44 M and CD44 U: *CD44* methylated- and unmethylated-specific primers; CD24 M and CD24 U: *CD24* methylated- and unmethylated-specific primers. (E) FACS analyses of the expressions of CD44 and CD24 in NSR, ANSR (5-Aza-pre-treated NSR) and SNSR (SAM-pre-treated NSR). (F-H) Effects of 5-Aza or SAM pre-treatment on the percentage of CD44^+^/CD24^-^ cells (F), CD44^+^ cells (G) and CD24^+^ cells (H) in NSR. For A, C, F, G and H, Data represent mean±SEM (*n* = 3). \**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .001.Figure 4

The Expression of CSC Markers CD44 and CD24 Was Correlated with DNA Methylation Status at Their Promoters During Apoptosis Reversal {#s0100}
-----------------------------------------------------------------------------------------------------------------------------------

During cancer development, cells acquire capabilities for malignant growth through both genetic and epigenetic mechanisms [@bb0160]. However, genetic advantages take longer to accumulate under selective pressure whereas epigenetic changes are faster-acting. To test if the transformation from NSCCs to CSCs by apoptosis reversal involves methylation/demethylation of specific genes, we first investigated the transcript levels of *CD44* and *CD24* in the reversed versus control MCF-7 cells. Consistent with flow cytometry results, the mRNA level of *CD44* was elevated while that of *CD24* was decreased in the reversed cells compared to control ([Figure 4](#f0020){ref-type="fig"}*A*). The expression data were confirmed by the methylation statuses of *CD44* and *CD24* in these two groups using methylation-specific PCR (MSP). In control cells, *CD44* were hypermethylated while *CD24* were hypomethylated ([Figure 4](#f0020){ref-type="fig"}*B*). In contrast, cells having undergone apoptosis reversal showed hypomethylation of *CD44* and hypermethylation of *CD24* ([Figure. 4](#f0020){ref-type="fig"}*B*). We then induced apoptosis reversal on FACS-sorted NSCCs. Reversed cells from NSCCs (CellEvent™-positive) (NSRs) were further sorted into CSC-like cells (CSC) and non-CSC cells (NCSCs) ([Supplementary Figure 8](#f0060){ref-type="graphic"}), and the mRNA levels of *CD44* and *CD24* in each group were consistent with their corresponding protein expressions ([Figure 4](#f0020){ref-type="fig"}*C*). In accordance, hypomethylation of *CD44* and hypermethylation of *CD24* were observed in CSCs when compared to NCSCs ([Figure 4](#f0020){ref-type="fig"}*D*). These results clearly indicated that methylation statuses of *CD44* and *CD24* determined the expression levels of these genes, and that apoptosis reversal drove the epigenetic modifications of *CD44* and *CD24* and gave rise to cells with CSC properties. The contribution by epigenetic regulations during the reversal of apoptosis and CSC generation was further confirmed by pre-treatment of NSCCs with the methylation inhibitor, 5-azacytidine (5-Aza) [@bb0165] (ANSRs), or the methyl group donor, S-(5\'-adenosyl)-L-methionine chloride dihydrochloride (SAM) [@bb0170] (SNSRs), before the induction of apoptosis ([Supplementary Figure 9](#f0065){ref-type="graphic"}). Both drugs suppressed the formation of CSC-like cells after apoptosis reversal, as indicated by the lower percentage of CD44^+^/CD24^-^ cells in ANSRs and SNSRs ([Figure 4](#f0020){ref-type="fig"}*E* and *F*). Meanwhile, CD44 expression was suppressed in SNSRs and CD24 expression was up-regulated in ANSRs ([Figure 4](#f0020){ref-type="fig"}*G* and *H*). These results suggest that the NSCC-to-CSC transition during apoptosis reversal is at least partially attributable to epigenetic regulations.

Discussion {#s0105}
==========

While previous studies showed that apoptosis reversal increased drug resistance, cell migration and invasion *in vitro* [@bb0065], our study is the first to demonstrate that cancer cells recovering from apoptosis reversal have higher tumorigenicity and metastatic potential *in vivo*, and that apoptosis reversal actually induced the formation of new CSCs from NSCCs in breast cancer cells. It has long been thought that cancer cell development is uni-directional: with CSCs at the apex, giving rise to progenitors and other differentiated cells [@bb0015]. Nevertheless, more recent studies have proposed the concept of CSC plasticity in which cells can transit between the non-CSC and the CSC states in both directions [@bb0175], [@bb0180], [@bb0185]. Our current study has clearly shown that the percentage of CSC-like cells (CD44^+^/CD24^-^) increased in the cell population which had undergone apoptosis reversal, and that these CSCs originated from NSCCs.

Besides, here we show that by inhibiting DNA methylation or demethylation before apoptosis induction, the CSC formation rate after apoptosis reversal is also reduced. Other epigenetic mechanisms [@bb0190] may also be involved. Therefore, it is critical to consider the involvement of chromatin remodeling during apoptosis reversal.

This study has clearly shown that through apoptosis reversal, NSCCs are transformed into CSCs, at least partly by the epigenetic modifications of CSC marker genes, and the resulting apoptosis-reversed cells undergo EMT [@bb0195] and possess enhanced tumorigenicity and metastatic properties *in vivo*. Thus when applying the commonly used tactic of eliminating cancer cells by triggering apoptosis [@bb0040], [@bb0045], [@bb0050], one needs to be mindful of at least ensuring cancer cells undergoing treatment have passed the point-of-no-return before terminating the treatment, in order to minimize the chances of relapse and/or metastasis.

The following are the supplementary data related to this article.Supplementary Figure 1Breast cancer cells were able to recover from apoptosis. (A) Schematics of cell generation for confocal imaging and western blotting to confirm the reversal of apoptosis. (B, D) Confocal images showing cellular morphological changes in MCF-7 cells (B) after STS induction (treated) and after the withdrawal of STS (reversed) and in T47D cells (D) after Paclitaxel induction (treated) and after withdrawal (reversed). Nuclei were stained by Hoechst 33342 (blue) while mitochondria were stained by MitoTracker^®^ Red CMXRos (red). A series of typical apoptotic morphologies were observed in the treated group including cell shrinkage, membrane blebbing, mitochondrial fragmentation and nuclear condensation. Scale bars: 20 μm. (C) Western blot analysis of poly (ADP-ribose) polymerase (PARP). Cleaved PARP (cPARP) was detected in MCF-7 cells treated with STS for 6 hours, confirming the activation of caspase. β-tubulin was used as a loading control. (E) Schematics of the sorting of treated, caspase-activated cancer cells (i) and solvent-treated and non-caspase-activated cancer cells (ii) by CellEvent™ staining. (F) Inverted microscopy showing both MCF-7 (upper panel) and T47D (lower panel) cells that recovered from apoptosis (reversed 24h and 48h) were viable and were able to proliferate. Solvent control (SC) had similar morphology as untreated cells. Scale bar: 100 μm.Supplementary Figure 1Supplementary Figure 2Continuous apoptotic treatment on sorted CellEvent™ positive cancer cell led to cell death. (A) Schematics of cell generation for flow cytometry and confocal imaging to confirm cell death after continuous inducers treatment. (B, D) Distributions of PI staining in CellEvent™ sorted MCF-7 cells in fresh medium or STS group (B) and in CellEvent™ sorted T47D cells in fresh medium or Paclitaxel group (D). Cells were treated with 2.5 μM STS for 6 hours (MCF-7) or with 5 μM Paclitaxel for 10 hours (T47D) then sorted into CellEvent™ positive and negative groups. Each group was further separated and put into either fresh medium or medium with its original inducers for another 24 hours. All CellEvent™ positive and negative cells under additional 24 hours' induction had 100% PI positive staining. (C, E) Percentage of cells with PI positive staining. CE +ve: sorted CellEvent™ positive cells. CE --ve: sorted CellEvent™ negative cells. Data represent mean±SEM. (*n* = 3). \*\*\**P* \< .001. n.d.: not detected.Supplementary Figure 2Supplementary Figure 3Confocal imaging on the morphological changes in the continuous treated CellEvent™ positive and negative cells. Confocal images showing cellular morphological changes in both CellEvent™ positive and negative cells after continuous STS (MCF-7 cells) (A) or paclitaxel (T47D cells) (B) induction or putting into fresh medium for recovery. Nuclei were stained by Hoechst 33342 (blue) while mitochondria were stained by MitoTracker^®^ Red CMXRos (red). A series of typical apoptotic morphologies were observed in the continuous treated groups including cell shrinkage, membrane blebbing, mitochondrial fragmentation and nuclear condensation. Scale bars: 20 μm.Supplementary Figure 3Supplementary Figure 4Schematics of *in vitro* and *in vivo* tumorigenicity assays using mammosphere culture and xenograft transplantation. (A) apoptosis-reversed MCF-7 cells; (B) solvent control; (C) untreated cells. Upper panel in each case: mammosphere culture; lower panel: xenograft transplantation.Supplementary Figure 4Supplementary Figure 5MCF-7 cells reversed from apoptosis showed increased tumorigenicity *in vivo* as determined using a xenograft model in nude mice. The tumors harvested from the mammary fat pads of nude mice in the reversed group were generally larger than those in the solvent control and the untreated groups, regardless of the number of MCF-7 cells used in the injection. The tumors formed in the 50,000-reversed cells group were also larger than those in the 10,000-reversed cells group. No visible tumor was formed in the groups injected with 10,000 solvent-treated cells or 10,000 untreated cells.Supplementary Figure 5Supplementary Figure 6Confocal images showing immunofluorescence detection of CD44 and CD24 in reversed, solvent control and untreated MCF-7 cells (A) and xenografts (B). Reversal of apoptosis increased the percentage of cells expressing CD44 and decreased the percentage of cells expressing CD24. MDA-MB-231 was used as a positive control for CD44 staining. DAPI was used to stain the nuclei. Scale bar: 50 μm.Supplementary Figure 6Supplementary Figure 7Schematics of fluorescence-activated cell sorting (FACS) of non-stem cancer cells (NSCCs) for the subsequent apoptosis reversal experiments.Supplementary Figure 7Supplementary Figure 8Schematics for the isolation of CSCs and NCSCs from NSRs.Supplementary Figure 8Supplementary Figure 9Schematics for the pre-treatment of NSR with DNA-demethylating agent, 5-Aza, or methyl group donor, SAM, before the apoptosis reversal experiment.Supplementary Figure 9Supplementary materialImage 1
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